Patent: 10,357,571
✉ Email this page to a colleague
Summary for Patent: 10,357,571
Title: | Development of masked therapeutic antibodies to limit off-target effects |
Abstract: | In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker. |
Inventor(s): | Williams; John C. (Monrovia, CA), Zer; Cindy (Duarte, CA), Avery; Kendra N. (Pasadena, CA), Rodeck; Ulrich (Philadelphia, PA), Donaldson; Joshua M. (Lumberton, NJ), Kari; Csaba (Rosemont, CA) |
Assignee: | Thomas Jefferson University (Philadelphia, PA) City of Hope (Duarte, CA) |
Application Number: | 14/949,648 |
Patent Claims: | see list of patent claims |
Details for Patent 10,357,571
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2030-08-03 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2030-08-03 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |